Incorporating monoclonal antibodies into the therapy of multiple myeloma
- PMID: 22291081
- DOI: 10.1200/JCO.2011.40.4178
Incorporating monoclonal antibodies into the therapy of multiple myeloma
Comment on
-
Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.J Clin Oncol. 2012 Jun 1;30(16):1960-5. doi: 10.1200/JCO.2011.37.7069. Epub 2012 Jan 30. J Clin Oncol. 2012. PMID: 22291084 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
